Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SCN1A | P35498 | 1/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.55 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525077 | 1.00 | LMNA (0.55) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL7615892 | 0.90 | CYP4F2 (0.55) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL4915922 | 0.90 | PDCD1 (0.70) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL17797890 | 0.88 | LMNA (0.49) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL855278 | 0.87 | MAPT (0.51) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL4336178 | 0.87 | LMNA (0.48) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL14690004 | 0.86 | TSHR (0.57) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL560828 | 0.86 | TSHR (0.57) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL1068955 | 0.86 | TSHR (0.57) | LMNACYP1A2CYP2D6POLBSCN1A | |
| SCHEMBL1784136 | 0.86 | TSHR (0.57) | LMNACYP1A2CYP2D6POLBSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190308934-A1 | Prodrugs of Chlorokynurenines | CEPHALON INC (US) | 2019-10-10 | — | — | US | disclosed |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8163958-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7956212-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201817-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
| US-20100197953-A9 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
| US-20190308934-A1 | Prodrugs of Chlorokynurenines | KMO, CYP2A13, KYNU | LMNA 2862/4885CYP1A2 40/4885CYP2D6 13/4885 |
| US-20090137834-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | COMT, DDT, DDC | LMNA 2387/4885CYP1A2 972/4885CYP2D6 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.